-transparent.png){kind=logo}
The distribution of acetylator phenotypes was studied in 244 unrelated Turkish subjects. Sulphadimidine and its acetylated metabolite were measured in 6 h plasma and 0-6 h urine samples after an oral dose of 10 mg/kg. Subjects with 37.5% or less acetylsulphadimidine in plasma were regarded as slow acetylators and the others as rapid acetylators. The mean plasma concentration of acetylsulphadimidine was about 2.5-times lower in slow acetylators. Urinary excretion of total sulphadimidine (free + acetylated) was also significantly lower in slow acetylators compared to rapid acetylators. The frequency of slow acetylators was 60.7% in the population (95% confidence interval 54.3% to 66.8%). Sulphadimidine acetylation showed no variation due to sex, age, body weight or pre-existing disease.
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
January 1988,
British journal of clinical pharmacology,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
June 1993,
Pharmacogenetics,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
September 1991,
British journal of clinical pharmacology,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
July 1987,
Journal of postgraduate medicine,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
December 1984,
International journal of clinical pharmacology, therapy, and toxicology,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
June 1981,
East African medical journal,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
January 1980,
General pharmacology,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
October 1989,
Die Pharmazie,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
January 1984,
International journal of clinical pharmacology research,
A Bozkurt, and
N E Basci, and
S Kalan, and
M Tuncer, and
S O Kayaalp
January 1998,
European journal of drug metabolism and pharmacokinetics,
